One panelist who voted ‘yes,’ Gabriel Alizaidy, M.D., of Maximus Health, argued that there was a “mismatch in real-world data ...
With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the ...
Novo Nordisk is escalating its legal battle against Eli Lilly over its GLP-1 drug marketing, notifying a federal court that ...
Following in the footsteps of Gilead Sciences, Merck & Co. has signed voluntary licensing agreements to enable access to its ...
This week on “The Top Line,” Fierce Healthcare and Life Sciences’ editor-in-chief steps behind the microphone for a solo ...
Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is ...
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results